Sibutramine usage in New Zealand: An analysis of prescription data by the intensive medicines monitoring programme

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 11, 2007, Pages 1217-1226

  Hill, Geraldine R ^a   Ashton, Janelle ^a   Harrison Woolrych, Mira ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Body mass index (BMI); Ethnicity; Intensive Medicines Monitoring Programme (IMMP); Pharmacovigilance; Prescribing patterns; Sibutramine

Indexed keywords

SIBUTRAMINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DRUG COST; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; ETHNIC DIFFERENCE; ETHNICITY; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEW ZEALAND; OBESITY; PATIENT COMPLIANCE; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SEX RATIO; TREATMENT DURATION; XEROSTOMIA;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE FACTORS; APPETITE DEPRESSANTS; COHORT STUDIES; CONTINENTAL POPULATION GROUPS; CYCLOBUTANES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; OBESITY; OCEANIC ANCESTRY GROUP; PHYSICIAN'S PRACTICE PATTERNS; PRODUCT SURVEILLANCE, POSTMARKETING; SEX FACTORS; TIME FACTORS;

EID: 36248959702     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1447     Document Type: Article

References (29)

1. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a Systematic Review. Arch Intern Med 2004; 164(9): 994-1003.
2. Kim SH, Lee YM, Jee SH, Nam CM. Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 2003; 11(9): 1116-1123.
3. O'Meara S, Riemsma R, Shirran L, Mather L, Ter Riet G. The clinical effectiveness and cost-effectiveness of sibutramine in the management of obesity: a technology assessment. Health Technology Assessment 2002; 6(6): 1-97.
4. Padwal R, Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. International Journal of Obesity & Related Metabolic Disorders Dec 2003; 27(12): 1437-1446.
5. Norris SL, Zhang X, Avenell A, et al. Efficacy of pharmacotherapy for weight loss in adults with Type 2 diabetes mellitus: a meta-analysis. [see comment]. Arch Intern Med 2004; 164(13): 1395-1404.
6. Vettor R, Serta R, Fabris R, Pagano C, Federspil G. Effect of sibutramine on weight management and metabolic control in Type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care 2005; 28(4): 942-949.
7. Barbehenn E, Lurie P, Wolfe S. Petition supplement to FDA outlining the rising number of cardiovascular events associated with the diet drug sibutramine (MERIDIA) (HRG Publication #1675) http://www.citizen.org/ publications/release.cfm?ID=7273. Accessed 19 April, 2006.
8. Wolfe SM, Sasich LD, Barbehenn E. Public Citizen Health Research Group. Petition to FDA to ban the diet drug sibutramine (MERIDIA) (HRG Publication #1613). http://www.citizen.org/publications/ print_release.cfm?ID=7160. Accessed 1 September, 2005.
9. Nisoli E, Carruba MO. A benefit-risk assessment of sibutramine in the management of obesity. Drug Saf 2003; 26(14):
10. -1048. 10. Committee for Proprietary Medicinal Products (CPMP). Committee for Proprietary Medicinal Products opinion following an article 31 referral. Sibuwamine: european agency for the evaluation of medicinal products; 2 December 2002 CPMP/4514/02/Final.
11. Abbott Laboratories (NZ) Ltd. New Zealand data sheet for Reductil. May 2006; http://www.medsafe.govt.nz/profs/Datasheet/r/Reductilcap.htm. Accessed 9 Jan 2007.
12. Gardin JM, Schumacher D, Constantine G, Davis KD, Leung C, Reid CL. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. JAMA 2000; 283(13): 1703-1709.
13. Coulter DM. PEM in New Zealand. In Pharmacovigilance, Mann RD, Andrecos E (eds). John Wiley & Sons Ltd: Chichester, England, 2002; 345-362.
14. New Zealand Health Information Service (NZHIS). Guide to NZHIS national collections: National Health Index (NHI). 22 Oct 2003; http://www.nzhis.govt.nz/collections/collections-nhi.html. Accessed 4 Dec, 2006.
15. Statistics New Zealand. Table 2b: ethnic group - up to three responses (Single and Combination) and sex for the census usually resident population count, 1991, 1996 and 2001 http://www.stats.govt.nz. Accessed October 2006.
16. Ministry of Health. Tracking the obesity epidemic: New Zealand 1977-2003. Wellington: Ministry of Health; December 2004. HP 4010.
17. Ministry of Health. The New Zealand health strategy. Wellington: Ministry of Health; 2000 (Available on-line at http://www.moh.govt.nz).
18. Ministry of Health. Healthy eating-healthy action: oranga kai-oranga pumau. A strategic framework. Wellington: Ministry of Health; March 2003. HP3606 (Available on-line at http://www.moh.govt.nz).
19. Ministry of Health. A portrait of health: key results of the 2002/03 New Zealand health survey. Wellington: Ministry of Health; August 2004 (Available on-line at http://www.moh.govt.nz).
20. Godoy-Matos A, Carraro L, Vieira A, et al. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metabol 2005; 90(3): 1460-1465.
21. Berkowitz RI, Wadden RA, Tershakovec AM, Cronquist JL. Behavior therapy and sibutramine for the treatment of adolescent obesity-a randomized controlled trial. JAMA 2003; 289(14): 1805-1812.
22. Salmond C, Crampton P. NZDep2001 index of deprivation user's manual. http://www.moh.govt.nz/moh.nsf/Files/phi-users-manual/ $file/phi-users-manual.pdf. Accessed 11 August, 2005.
23. Raymont A, Cumming J. New Zealand's primary health care strategy: what are the costs and how likely are the benefits? New Zealand Med J 2003; 116(1173): U416.
24. Ministry of Health. Modelling diabetes: forecasts to 2011. Wellington: Ministry of Health; March 2002. HP3491 (Available on-line at http://www.moh.govt.nz).
25. Avenell A, Broom J, Brown TJ, et al. Systematic Review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assessment (Winchester, England) 2004; 8(21): iii-iv.
26. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J. Pharmacotherapy for weight loss in adults with Type 2 diabetes mellitus [Systematic Review]. Cochrane Database Syst Rev 2006; (1).
27. Wadden TA, Womble LG, Sarwer DB, Berkowitz RI, Clark VL, Foster GD. Great expectations: "I'm losing 25% of my weight no matter what you say". J Consult Clin Psychol 2003; 71(6): 1084-1089.
28. Padwai R, Li SK, Lau DCW. Long-term pharmacotherapy for overweight and obesity: a Systematic Review and recta-analysis of randomized controlled trials. Int J Obes Rel Metabol Disord: J Int Assoc Study Obes. 2003; 27(12): 1437-1446.
29. Douketis JD, Macie C, Thabane L, Williamson DF. Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice, Int J Obes 2005; 29(10): 1153-1167.